ERBB2 and gastric cancer: Trastuzumab deruxtecan and Disitamab vedotin plus toripalimab (PD-1 blockade) have shown encouraging antitumor activity as 2nd-line treatments for HER2-positive GC.32,33 This chemotherapy-free regimen showed comparable efficacy and a lower incidence of hematological toxicity.